SHANGHAI – Simcere Pharmaceutical Group made headlines in December when it announced plans to go private and delist from the NYSE. As the first Chinese biopharmaceutical company to go public in the U.S. the longtime generics maker – and growing innovative drug developer – is used to taking on pioneering projects, and looks to be at it again.